68Ga–Prostate-Specific Membrane Antigen–Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI

Ahuja, Aashim; Taneja, Sangeeta; Thorat, Kiran; Jena, Amarnath

doi:10.1097/rlu.0000000000001874

Cited by 15 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another chronic granulomatosis inflammatory disorder that is known to express PSMA is Wegener’s granulomatosis [ 48 ]. Other inflammatory lung conditions that are known to express PSMA in [ 68 Ga]Ga-PSMA-11 scans are bronchiectasis, anthracosilicosis, and tuberculosis [ 49 – 51 ].…”

Section: Radiolabeled Psma Ligands: Physiological Uptake Variants Diagnostic Accuracy and Pitfallsmentioning

confidence: 99%

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Ceci

Oprea-Lager

Emmett

et al. 2021

Eur J Nucl Med Mol Imaging

252

184

View full text Add to dashboard Cite

Rationale The development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the data reproducibility within clinical trials. Finally, guidelines in PSMA-PET interpretation are needed to communicate the exact location of findings to referring physicians, to support clinician therapeutic management decisions. Methods A panel of worldwide experts in PSMA-PET was established. Panelists were selected based on their expertise and publication record in the diagnosis or treatment of PCa, in their involvement in clinical guidelines and according to their expertise in the clinical application of radiolabeled PSMA inhibitors. Panelists were actively involved in all stages of a modified, nonanonymous, Delphi consensus process. Results According to the findings obtained by modified Delphi consensus process, panelist recommendations were implemented in a structured report for PSMA-PET. Conclusions The E-PSMA standardized reporting guidelines, a document supported by the European Association of Nuclear Medicine (EANM), provide consensus statements among a panel of experts in PSMA-PET imaging, to develop a structured report for PSMA-PET in prostate cancer and to harmonize diagnostic interpretation criteria.

show abstract

Section: Radiolabeled Psma Ligands: Physiological Uptake Variants Diagnostic Accuracy and Pitfallsmentioning

confidence: 99%

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Ceci

Oprea-Lager

Emmett

et al. 2021

Eur J Nucl Med Mol Imaging

252

184

View full text Add to dashboard Cite

show abstract

“…Of course, there is no absolute discriminative answer generated by these questions, but available data about patterns of uptake (tends to be much higher in PCa, despite some potential overlap in organs such as the lungs or liver), knowledge of CT/MRI morphological disease patterns and the understanding of the natural history of various neoplasms allow interpreters to produce more accurate predictions, for example, indicating biopsies with more effectiveness. A list including all the reported cases of nonprostatic diseases with PSMA ligand uptake on PET imaging is summarized in Table 1 [4,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32].…”

Section: Nonprostatic Diseasesmentioning

confidence: 99%

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

et al. 2020

View full text Add to dashboard Cite

PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes.

show abstract

“…These factors could potentially limit the utility of PSMAtargeted imaging and thus far have not been completely evaluated. For instance, although infections such as tuberculosis (33,36), as well as chronically inflamed tissues (37), can show PSMA-targeted radiotracer uptake, the potential for higher specificity than is achievable with 18 F-FDG could indicate a promising role for PSMA-targeted agents in NSCLC and SCLC in terms of differentiating reactive mediastinal and hilar lymph nodes and inflammatory lung parenchymal findings from true tumor involvement.…”

Section: Lung Cancermentioning

confidence: 99%

Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms

et al. 2018

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.

show abstract

68Ga–Prostate-Specific Membrane Antigen–Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI

Cited by 15 publications

References 11 publications

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms

Contact Info

Product

Resources

About